

!

Pharmacist Training on the Administration of Long-Acting Injectable Antipsychotics (LAIs)

!  
"#\$%&!'()\*(!  
!

\*+, -./0!1 2 3!4\$.5%-6.78!!  
9, ++% :%! , ;!<=0- >0?8! 2!<=0- >0?%#7.?0+!@?.%\$?%6'!A<B!  
C0>D0!E08!A\$67-#?7., \$0+!@.7%!  
FG) )!HI! \*+%7?=%-! 15%!I!@#.7%!J&FF'!C0 > D0'!\*K!FFL&F!!  
"#\$%&\$'()\*!+!, -(!  
! "##\$%&'()\*+ , \*-.!  
/ '0-\$%'&'! "1201301%&()\*+ , \*-.&453-\*20"1&  
/ 0110-0&&((2!3!\$'4)0!56578!  
9: ;7<!;==>56?7!\$'9: ;7<!;==>557@!

**Online Home-Study Modules  
Now – June 10, 2022**

**Live Training  
Saturday, June 11, 2022  
8:00 a.m. or 1:00 p.m.  
Pharmacist Training on the Administration of  
Long-Acting Injectable Antipsychotics (LAIAs)**

**GENERAL INFORMATION**

**Fee:** \$500.00

**Ways to Register and Payment Method:**

Online Registration: <https://cvent.me/34nbNZ>     Debit Card     Credit Card

**Target Audience:** Pharmacists

**Financial Support:** This activity is supported by an educational grant from Janssen Scientific Affairs, LLC and Alkermes, Inc.

**Meeting Location:** Florida A&M University College of Pharmacy and Pharmaceutical Sciences, Institute of Public Health, Tampa Bay Instructional Site, 3500 E. Fletcher Ave. Suite #133, Tampa, FL 33613.

*Note: As the temperature in meeting rooms vary, participants are encouraged to bring a sweater or jacket with them.*

**Americans with Disabilities Act:** If a participant requires a reasonable accommodation according to the Americans with Disabilities Amendment Act (ADAA), please contact the **Office of Continuing Pharmacy Education** at (850) 599-3240 at least ten working days before the start of the event.

**Grievance Policy:** All grievances regarding the Florida A&M University College of Pharmacy and Pharmaceutical Sciences, Institute of Public Health should be communicated in writing to the director of the Office of Pharmacy Continuing Education. Grievances will be reviewed and acknowledged by mail within 30 days after receipt. Unsatisfactory responses to grievances should be communicated in writing to the dean of FAMU-CoPPS, IPH.

**Cancellation and Refund Policy:** All cancellation requests must be made in writing. Requests may be made by email to [tenele.dennard@famu.edu](mailto:tenele.dennard@famu.edu) or fax to the attention of Tenele Dennard at (850) 599-3347. If you need to communicate with Mrs. Dennard, you may contact her at (850) 599-3240. All requests for refunds made prior to **May 30**, will be honored and charged a \$25 administrative fee. No refunds will be given for cancellations made after **May 30**.

**Live Training Policy:** Once registered, participants will be contacted regarding access to the six and half (6.5) hours of online home study modules to be completed **before** the three (3) hour live

hands-on training on **June 11, 2022** in Tampa, Fl. Due to COVID restrictions, attendance to a future live training is only allowable IF the future live training session is not full. Future training dates and locations are TBD. Given each live training session is limited to ten (15) participants, with priority given to those paid registrants, completion during your allotted time is strongly suggested. CE hours cannot be processed until the full training is complete. **NOTE: If the program does not meet the minimum number of registrants, the live training will be canceled with the option for a refund or attendance at an upcoming live training listed above.**

**Attendance and Evaluation Forms:** Participants must complete the Online modules, attend the Live Training, and complete Speaker and Program evaluations to receive credits. As confirmation of attendance, participants will be required to complete a continuing education attendance form. Each participant will receive an evaluation link to complete the on-line evaluation form.

**Use of Trade Names:** The trade names of the drugs and delivery systems in this module are for the purpose of product identification only. This activity does not intend to imply endorsement for any commercial products discussed.

**Continuing Education Credits:** Continuing Education Credits will be posted on the CE Broker and CPE Monitor upon completion of all nine and half (9.5) hours: six and half (6.5) hours Home-Study and three (3) hours Live Training.

**Accreditations:** The Florida Department of Health Board of Pharmacy approves Florida A&M University College of Pharmacy and Pharmaceutical Sciences as a provider of Continuing Pharmacy Education (CPE).



Florida A&M University College of Pharmacy and Pharmaceutical Sciences is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of Continuing Pharmacy Education.



ACPE is working in partnership with the National Association of Boards of Pharmacy (NABP) to authenticate and store data for completed CPE units received by pharmacists and pharmacy technicians from ACPE-accredited providers. Pharmacists and pharmacy technicians may obtain their NABP e-Profile ID, the Unique Identification number required when registering for a CPE activity from an ACPE-accredited provider by going to [www.nabp.net](http://www.nabp.net).

## TARGET AUDIENCE

**Pharmacists:** This program is **approved** for the following:

**Home Study** credit hours for pharmacists. Offering six and half contact hours (6.5 CEUs) of General CE Broker Course Tracking Number: 20-718759.

**AND**

**Live** credit hours for pharmacists. Offering three contact hours (3.0 CEUs) of General CE Broker Course Tracking Number: 20-858505.

## PROGRAM GOAL

Knowledge and application-based continuing education activities are guided by the ACPE Standards and Quality Assurance Procedures for ACPE-accredited providers of Continuing Pharmacy Education offering Certificate Programs in Florida. The goal of this program is to provide an opportunity for program participants to acquire knowledge and apply the necessary skills for administering Long-Acting Antipsychotic Injections (LAIAs).

## PROGRAM OUTCOMES

Specific presentation objectives are included in the schedule. Through participation in the program, participants will be able to do the following:

1. Summarize the clinical implications and benefits from a pharmacist-physician collaboration for caregivers and patients utilizing antipsychotic long-acting injectables.
2. Develop strategies to identify and manage personal biases about mental health disorders.
3. Recognize and understand the impact psychosocial factors have on patients suffering from mental health disorders.
4. Describe the signs, symptoms, diagnostic criteria, and basic pathophysiology of schizophrenia, schizoaffective, and bipolar disorder.
5. Describe the evidence and rationale for the use of long-acting antipsychotics to prevent relapse in schizophrenia, schizoaffective, and bipolar disorder.
6. Outline the dosages, mechanisms of action, pharmacokinetics, adverse events, significant drug interactions, and warnings/precautions for long-acting injectable antipsychotics used in the treatment of schizophrenia, schizoaffective, and bipolar disorder.
7. Landmark and identify intramuscular and subcutaneous injection sites.
8. Identify equipment for intramuscular and subcutaneous injections.
9. Demonstrate the appropriate technique for intramuscular and subcutaneous administration of long-acting antipsychotic injections.

## PROGRAM REQUIREMENTS

Participant Responsibilities: In order to satisfy the 9.5-hour CE requirements of the Pharmacist Administration of Long-Acting Antipsychotic Injections Program, participants must complete both the Online Home-Study modules and live training. Activities include module pre-tests, recorded lectures, post-tests ( $\geq 70\%$  required), injection technique assessment, and speaker and program evaluation.

### **Required Computer Hardware/Software**

For the Online Home-study Modules, please ensure the computer system you plan to use meets the following minimum requirements:

- **Operating System:** Windows 98 or higher & Macintosh 2.2 or higher
- **Internet Browser (Mac & Windows):** Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher, & Opera 5 or higher
- **Broadband Internet connection:** Cable, High-speed DSL & any other medium that is internet accessible
- **Peripherals:** Computer speakers or headphones
- **Monitor Screen Resolution:** 320 x 480 or higher
- **Media Viewing Requirements:** Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5

## **Privacy and Confidentiality Policy**

We (the Florida A&M University College of Pharmacy and Pharmaceutical Sciences Office of Continuing Pharmacy Education) do not share your personal information to entities outside of Florida A&M University College of Pharmacy or entities utilized to provide services to you (Cvent, Instructure, Inc., Canvas LMS, etc.). Information provided by you through Cvent is utilized to communicate regarding CPE activities and events, and to provide you access to the online module platform (Canvas, through Instructure, Inc.) for Self-Study CPE Activities. This information includes: name, email, and phone number. For more information on Florida A&M University's Privacy and Confidentiality Policy, visit: <http://www.famu.edu/index.cfm?legalnotices&TermsofUse>. For more information on Instructure, Inc.'s Privacy and Confidentiality Policy, visit: <https://www.instructure.com/canvas/privacy>. For more information on Cvent's, Privacy and Confidentiality Policy, visit: <https://www.cvent.com/en/cvent-global-privacy-policy>.

## **PROGRAM STRUCTURE**

Through engagement in the 6.5-hour Online Home-Study comprehensive series and the 3-hour live hands-on training, participants will be able to earn the required hours of CE in order to administer LAIAs in the State of Florida. Participants will receive access to handouts, bibliographies, and recorded lectures to be completed before the live 3-hour training. The program is structured for the Online Home-Study modules to be completed at the participant's pace but should be completed **before June 11, 2022**. Participants will be assessed. Use of Trade Names: The trade names of the drugs and delivery systems in this module are for the purpose of product identification only. This activity does not intend to imply endorsement for any commercial products discussed.

### **Online Home-Study Comprehensive Series**

The participant must be provided access to the six and half hours of Online Home-Study to be completed. For each online module, participants will be provided access to presentation documents and recorded lectures. This aspect of the program emphasizes the psychosocial and treatment aspect of those disorders which can be treated by LAIAs (Schizophrenia, Schizoaffective, and Bipolar disorder), with emphasis on the pharmacist's role in treating this population. As part of the online component, participants will take a pre-test to determine their base knowledge on the topics, and following the modules, they will take a post-test as their assessment, in which a score of  $\geq 70\%$  is needed to satisfy completion.

### **Practical Live Hands-on Training**

Upon completion of the Online Home-Study modules, participants will be able to attend the live hands-on training for learning how to administer the specific LAIAs. As part of the live training, participants will be assessed on their demonstration of the various injection techniques. Upon completion of the hands-on training, participants will assess all faculty in the program (from the Online Home-Study modules and Live Hands-on training), and ultimately assess the program as a whole.

## **About Our Faculty**

### **Dr. Rajiv Tandon ~ Module 1**

Rajiv Tandon, MD, is the Professor and Chairman of Psychiatry at the WMED Homer Stryker College of Medicine in Kalamazoo, Michigan. Dr. Tandon has authored more than 400 scientific

publications and given over 1200 national and international scientific presentations. He has received several awards for research and teaching in schizophrenia, including the 2010 and 2016 SIRS (International Schizophrenia Research Society) Senior Researcher of the Year awards for the most cited paper in schizophrenia between 2008-10 (2010) and the most downloaded paper in schizophrenia between 2014-2016 (2016). Dr. Tandon has received the Exemplary Psychiatrist Award from the National Alliance for Mental Illness on three occasions: in 2009, 2012, and 2015. He was a member of the DSM-5 workgroup on schizophrenia and related psychotic disorders and is a member of the World Psychiatry Association Pharmacopsychiatry Section. He is the immediate Past-President of the Florida chapter of the National Alliance for Mental Illness and the immediate Past-President of the Florida Psychiatric Society. His primary areas of clinical and research interest are the neuropharmacology of schizophrenia, differences between typical and atypical antipsychotic agents, dimensions of schizophrenic psychopathology, neuroendocrine and polysomnographic abnormalities in schizophrenia, and the evidence-based treatment of schizophrenia and other major mental disorders.

### **Dr. Claudia Vicencio ~ Module 2**

Claudia Vicencio, Ph.D., LCSW, LMFT, is the Clinical Supervisor for Outpatient Behavioral Health at Memorial Regional Hospital in Hollywood, Florida. Along with Alberto Augsten, PharmD, BCPP, DABAT, she also created and managed multiple innovative programs to treat opioid and other substance use disorders—including the award-winning Mothers in Recovery Program. Dr. Vicencio is passionate about designing programs that address the social determinants of health by connecting hospital services to community resources. She is an engaging and dynamic speaker and educator. Her research and clinical practice expertise include the treatment of drug addiction in pregnancy, social work-pharmacy collaboration, evidence-based models for behavioral health practice, and mediating the impact of childhood adversity on adults with behavioral health conditions. Dr. Vicencio obtained her Ph.D. in Social Work, focusing her doctoral research on the impact of childhood adversity on adults' attitudes toward seeking professional mental health treatment. Her previous work includes managed care, inpatient psychiatry the work with adolescents and their families. Dr. Vicencio is dedicated to improving access to effective behavioral health treatment for vulnerable populations and aspires to live in a world where childhood adversity is eradicated through person-centered care for adults with psychiatric disorders.

### **Dr. Leonard Rappa ~ Module 3**

Dr. Rappa is a tenured professor that began his academic career with Florida A&M University, College of Pharmacy and Pharmaceutical Sciences in December of 1998. Dr. Rappa received his Doctor of Pharmacy degree (with honors) in 1995 from Nova Southeastern University, and subsequently became their first Psychopharmacology specialty resident from 1995-1996. After completion of his residency, he moved to Sarasota, Florida to become Sarasota Memorial's Psychiatric Pharmacy Specialist. In 1997, Dr. Rappa became Board Certified as a Psychiatric Pharmacist and maintained that certification yearly. In December of 1998, he returned to South Florida to assume a full-time faculty position with Florida A&M University's Miami Campus, College of Pharmacy. At that time, he established a practice site at Memorial Regional Hospital in Hollywood, Florida, teaching the sixth-year doctoral students on their Psychiatry Pharmacy clinical clerkship rotation. At Memorial, he integrated himself and the students well into the non-teaching environment, making the milieu very open to a pseudo-teaching atmosphere. Over the next 18 years of practice, he trained hundreds of students, residents, and other pharmacists in psychopharmacology. With his guidance, the internal clinical pharmacy services evolved, and at the time he departed, there were several full-time psychiatric pharmacists and a specialized Post-graduate Year II (PGY-2) pharmacy resident. At the beginning of 2017, he established a new

clinical practice in Fort Lauderdale at Broward Health Imperial Point and has made great inroads in establishing clinical pharmacy services to the Behavioral Health patients and staff.

**Dr. Shari Allen ~ Module 4**

Dr. Allen earned her PharmD from Florida A&M University College of Pharmacy and Pharmaceutical Sciences. After graduation, she completed an ASHP accredited PGY-1 (General Practice) and PGY-2 (Psychiatry) residency at the Buffalo Psychiatric Center in Buffalo, NY. She is now an Associate Professor of Pharmacy Practice at Philadelphia College of Osteopathic Medicine (PCOM) - School of Pharmacy, where she has been for eight years. Dr. Allen teaches in a Therapeutics Course, Pharmacy Practice Lab, and a Psychiatry Elective at PCOM-SOP. She also maintains a pharmacy practice site at the Atlanta VA Medical Center in Decatur, Georgia. Dr. Allen volunteers her time with organizations such as the College of Psychiatric and Neurologic Pharmacists (CPNP), ASHP, Georgia Pharmacy Association (GPhA), and the National Alliance on Mental Illness (NAMI) when she is not teaching at PCOM-SOP.

**Ms. Hannah Phillips ~ Module 6**

Ms. Hannah Phillips, MSN, PMHNP-BC, is a Psychiatric Nurse Practitioner based out of Orlando, Florida. Ms. Phillips currently works at Big Bear Behavioral Health and Grace Medical Home. Ms. Phillips received her BSN and MSN degrees in the Psychiatric-Mental Health Nurse Practitioner Program (PMHNP) from the University of Florida. She is a member of the National Alliance on Mental Illness and the American Psychiatric Nurses Association. Ms. Phillips currently serves as an adjunct clinical facility preceptor for PMHNP students from the University of Florida. Ms. Phillips' passions include but are not limited to: cats, Florida history, photography, urban exploration, and LAIA.

**Ms. Ana Alonso ~ Modules 5 & 6**

Ms. Ana Alonso received her Associate's Degree in Nursing from Valencia Community College in 1996, her BSN from Nova Southeastern University in 2013, and is currently working to receive her Doctor of Nursing Practice Degree from the University of South Alabama. Ms. Alonso has worked as a Psychiatric Registered Nurse, and she has 22 years of experience in behavioral health with Aspire Health Partners, formerly known as Lakeside Behavioral Healthcare in Orlando, Florida. During her tenure with Aspire Health Partners, she oversaw the administration of LAIAs which had approximately 600 patients on the injections, for which she averaged 350 injections per month. Given her expertise, she has seen firsthand the benefits of LAIAs over oral medication, not only from the patient's perspective but also the practitioner's perspective. Ms. Alonso is very excited about training pharmacists and looks forward to instructing on the proper techniques for intramuscular and subcutaneous injections.

## PROGRAM SCHEDULE

	Topic, Faculty, and Activity	Objectives
<b>MODULE 1</b>	<p><b>Presentation:</b> The Physician’s Perspective on the Role of Pharmacists in Administering Long-Acting Injectable Antipsychotics</p> <p><b>UAN# 0011-0000-21-002-H01-P, Knowledge-Based</b>  <b>0.5 Contact Hours</b>  <b>Initial Release: 01/29/2021</b>  <b>Expiration: 01/29/2024</b></p> <p><b>Faculty:</b> Rajiv Tandon, MD, DLFAPA, Professor and Chair, Department of Psychiatry, Homer Stryker Western Michigan University College of Medicine, Kalamazoo, Michigan</p> <p><b>Activities:</b></p> <ol style="list-style-type: none"> <li>1. Pre-test</li> <li>2. Module Review</li> <li>3. Post-test (score <math>\geq 70\%</math> to complete requirements)</li> </ol>	<ol style="list-style-type: none"> <li>1. Define the statute language allowing for pharmacists to administer antipsychotic long-acting injectable.</li> <li>2. Describe and differentiate the psychiatric patient population utilizing antipsychotic long-acting injectables.</li> <li>3. Summarize the clinical implications and benefits from a pharmacist-physician collaboration for caregivers and patients utilizing antipsychotic long-acting injectables.</li> </ol>
<b>MODULE 2</b>	<p><b>Presentation:</b> Psychosocial Considerations for Long-Acting Injectable Antipsychotic Providers</p> <p><b>UAN# 0011-0000-21-001-H01-P, Knowledge-Based</b>  <b>0.5 Contact Hours</b>  <b>Initial Release: 01/29/2021</b>  <b>Expiration: 01/29/2024</b></p> <p><b>Faculty:</b> Claudia Vicencio, Ph.D., LCSW, LMFT, Clinical Supervisor, Outpatient Behavioral Health, Memorial Regional Hospital, Hollywood, Florida</p> <p><b>Activities:</b></p> <ol style="list-style-type: none"> <li>1. Pre-test</li> <li>2. Module Review</li> <li>3. Post-test (score <math>\geq 70\%</math> to complete requirements)</li> </ol>	<ol style="list-style-type: none"> <li>1. Define stigma and discuss the prevalence of stigma in healthcare professionals.</li> <li>2. Describe the impact of stigma on individuals’ access to care and the effectiveness of treatment.</li> <li>3. Develop strategies to identify and manage personal biases about mental health disorders.</li> <li>4. Recognize and understand the impact psychosocial factors have on patients suffering from mental health disorders.</li> </ol>



	Topic, Faculty, and Activity	Objectives
MODULE 3	<p><b>Presentation:</b> Managing Schizophrenia and Schizoaffective Disorder with Long-Acting Injectable Antipsychotics</p> <p><b>UAN# 0011-0000-21-003-H01-P, Knowledge-Based 2 Contact Hours Initial Release: 01/29/2021 Expiration: 01/29/2024</b></p> <p><b>Faculty:</b> Leonard Rappa, Pharm.D., BCCP, CPh, Professor, Division of Pharmacy Practice, FAMU College of Pharmacy and Pharmaceutical Sciences, Institute of Public Health, Davie Instructional Site, Davie, Florida</p> <p><b>Activities:</b></p> <ol style="list-style-type: none"> <li>1. Pre-test</li> <li>2. Module Review</li> <li>3. Post-test (score <math>\geq 70\%</math> to complete requirements)</li> </ol>	<ol style="list-style-type: none"> <li>1. Describe the signs, symptoms, diagnostic criteria, and basic pathophysiology of schizophrenia and schizoaffective disorder.</li> <li>2. Describe the evidence and rationale for the use of long-acting antipsychotics to prevent relapse in schizophrenia and schizoaffective disorder.</li> <li>3. Outline the dosages, mechanisms of action, pharmacokinetics, adverse events, significant drug interactions, and warnings/precautions for long-acting injectable antipsychotics used in the treatment of schizophrenia and schizoaffective disorder.</li> <li>4. Explain appropriate safety monitoring for LAIAs used in the treatment of schizophrenia and schizoaffective disorder.</li> <li>5. Identify important counseling information to be discussed with patients being administered LAIAs for the treatment of schizophrenia and schizoaffective disorder.</li> <li>6. Recognize the patient and family psychosocial perspective and contributions to patient acceptance and recognition of treatment needs.</li> </ol>
MODULE 4	<p><b>Presentation:</b> Bipolar Disorder and Long-Acting Injectable Antipsychotics</p> <p><b>UAN# 0011-0000-21-007-H01-P, Knowledge-Based 1 Contact Hour Initial Release: 01/29/2021 Expiration: 01/29/2024</b></p> <p><b>Faculty:</b> Shari Allen, Pharm.D., BCPP, Assistant Professor of Pharmacy Practice, Philadelphia College of Osteopathic Medicine – School of Pharmacy, Suwanee, Georgia</p> <p><b>Activities:</b></p> <ol style="list-style-type: none"> <li>1. Pre-test</li> <li>2. Module Review</li> <li>3. Post-test (score <math>\geq 70\%</math> to complete requirements)</li> </ol>	<ol style="list-style-type: none"> <li>1. Describe the signs, symptoms, diagnostic criteria, and basic pathophysiology of bipolar disorder.</li> <li>2. Describe the evidence and rationale for the use of long-acting antipsychotics to prevent relapse in bipolar disorder.</li> <li>3. Outline the dosages, mechanisms of action, pharmacokinetics, adverse events, significant drug interactions, and warnings/precautions for long-acting injectable antipsychotics used in the treatment of a bipolar disorder.</li> <li>4. Explain appropriate safety monitoring for LAIAs used in the treatment of a bipolar disorder.</li> <li>5. Identify important counseling information to be discussed with patients being administered LAIAs for the treatment of a bipolar disorder.</li> <li>6. Recognize the patient and family psychosocial perspective and contributions to patient acceptance and recognition of treatment needs.</li> </ol>

	Topic, Faculty, and Activity	Objectives
<p><b>MODULE 5</b></p>	<p><b>Presentation:</b> Long-Acting Injectable Antipsychotics: Basics and Beyond</p> <p><b>UAN# 0011-0000-21-004-H01-P, Application-Based</b>  <b>2.5 Contact Hours</b>  <b>Initial Release: 01/29/2021</b>  <b>Expiration: 01/29/2024</b></p> <p><b>Faculty:</b>  Hannah Phillips, MSN, PMHNP-BC, Psychiatric Nurse Practitioner, Big Bear Behavioral Health and Grace Medical Home, Orlando, Florida</p> <p><b>Activities:</b></p> <ol style="list-style-type: none"> <li>1. Pre-test</li> <li>2. Module Review</li> <li>3. Post-test (score <math>\geq 70\%</math> to complete requirements)</li> </ol>	<ol style="list-style-type: none"> <li>1. Analyze the benefits of utilizing long-acting injectable antipsychotic medications.</li> <li>2. Illustrate the advantages of LAIAs over oral formulations in first-episode psychosis.</li> <li>3. Use key factors to consider when selecting a second-generation LAIAs for an individual patient.</li> <li>4. Compare barriers to using SGA LAIA therapy and potential strategies to overcoming these barriers in clinical practice.</li> <li>5. Examine how to obtain informed consent and the 5 Rights of Medical Administration.</li> <li>6. Differentiate intramuscular and subcutaneous injection sites.</li> <li>7. Distinguish physical space requirements for administering a long-acting antipsychotic injection.</li> <li>8. Discuss Occupational Safety and Health Administration regulations for the prevention of employee exposure to bloodborne pathogens and needle stick injury at worksites where injections are administered.</li> <li>9. Outline principles and procedures for injection storage and handling.</li> <li>10. Describe the signs and symptoms of generalized and local adverse reactions to long acting antipsychotic injections and procedures that pharmacists should follow to manage various adverse reactions.</li> <li>11. Educate patients about potential adverse reactions following the receipt of a long acting antipsychotic injection and how to manage them.</li> <li>12. Describe appropriate documentation and follow-up after injection administration.</li> </ol>
<p><b>MODULE 6: LIVE TRAINING SATURDAY</b>  <b>Saturday, June 11, 2022</b></p>	<p><b>Presentation:</b> Long-Acting Injectable Antipsychotic Hands-on Training: Basics and Beyond</p> <p><b>UAN# 0011-0000-21-027-L01-P, Application-Based</b>  <b>3.0 Contact Hours</b>  <b>Initial Release: 01/29/2021</b>  <b>Expiration: 01/29/2024</b></p> <p><b>Faculty:</b>  Hannah Phillips, MSN, PMHNP-BC, Psychiatric Nurse Practitioner, Big Bear Behavioral Health and Grace Medical Home, Orlando, Florida</p> <p>Ana Alonso, BSN, Registered Nurse, Doctor of Nursing Student, University of South Alabama, Orlando, Florida</p> <p><b>Moderator:</b>  Soheyra Mahdavian, Pharm.D., BCGP, Professor, Division of Pharmacy Practice, Florida A&amp;M University College of Pharmacy and Pharmaceutical Sciences, Institute of Public Health, Tallahassee, Florida</p> <p><b>Activities:</b></p> <ol style="list-style-type: none"> <li>1. Overview of CPA</li> <li>2. Injection demonstration and technique assessment (must obtain 'satisfactory' on all techniques)</li> </ol> <p>Speaker and Program evaluation</p>	<ol style="list-style-type: none"> <li>1. Differentiate and employ intramuscular and subcutaneous injection sites.</li> <li>2. Examine equipment for intramuscular and subcutaneous injections.</li> <li>3. Differentiate techniques for injection preparation for the various medications.</li> <li>4. Demonstrate the appropriate technique for intramuscular and subcutaneous administration of long-acting antipsychotic injections.</li> <li>5. Distinguish physical space requirements for administering a long-acting antipsychotic injection.</li> </ol>



FLORIDA AGRICULTURAL AND MECHANICAL UNIVERSITY